Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Pharmaceuticals ETF (NY:XPH)

57.93 +0.04 (+0.07%)

Streaming Delayed Price Updated: 10:28 AM EDT, Jun 5, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	4,599
Open	57.88
Bid (Size)	57.90 (600)
Ask (Size)	58.00 (200)
Prev. Close	57.89
Today's Range	57.88 - 58.35
52wk Range	40.26 - 60.73
Shares Outstanding	36,002
Dividend Yield	0.42%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio? ↗

June 04, 2026

Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration—key factors shaping their long-term investor appeal.

Via The Motley Fool

Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗

June 04, 2026

Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.

Via The Motley Fool

Performance

YTD	+4.9%	+4.9%
1 Month	-3.1%	-3.1%
3 Month	+4.8%	+4.8%
6 Month	+6.7%	+6.7%
1 Year	+40.8%	+40.8%

More News

ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts ↗

March 10, 2026

Via Stocktwits

Why Did AQST Stock Plunge 40% In Pre-Market Today? ↗

January 09, 2026

Via Stocktwits

Why Did CANF Stock Soar 40% In Pre-Market Today? ↗

March 04, 2026

Via Stocktwits

TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint ↗

March 03, 2026

Via Stocktwits

FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development ↗

February 18, 2026

Via Stocktwits

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results ↗

February 10, 2026

Via Stocktwits

Why Did CRMD Stock Crash 28% Today? ↗

January 08, 2026

Via Stocktwits

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗

November 12, 2025

Via Benzinga

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

Via Benzinga

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗

September 29, 2025

Via Benzinga

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

Via Investor's Business Daily

Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗

September 08, 2025

Via Benzinga

Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy. ↗

August 22, 2025

Via Investor's Business Daily

Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗

August 01, 2025

Via Benzinga

Novo Nordisk Shares Plunge Amid Leadership Shakeup (NYSE:NVO)

July 29, 2025

Via MarketMinute

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Via Benzinga

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Via Benzinga

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' ↗

June 20, 2025

Via Benzinga

Trump Sparks New Chapter In Transatlantic Trade War: What The US Buys From Europe ↗

May 23, 2025

Via Benzinga

Here's How Trump Plans To Tackle Drug Prices, And Why It Might Not Work ↗

May 20, 2025

Via Investor's Business Daily

Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion ↗

May 19, 2025

Via Benzinga

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks ↗

May 08, 2025

Via Benzinga

Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report ↗

April 28, 2025

Via Stocktwits

Frequently Asked Questions

Is State Street SPDR S&P Pharmaceuticals ETF publicly traded?

Yes, State Street SPDR S&P Pharmaceuticals ETF is publicly traded.

What exchange does State Street SPDR S&P Pharmaceuticals ETF trade on?

State Street SPDR S&P Pharmaceuticals ETF trades on the New York Stock Exchange

What is the ticker symbol for State Street SPDR S&P Pharmaceuticals ETF?

The ticker symbol for State Street SPDR S&P Pharmaceuticals ETF is XPH on the New York Stock Exchange

What is the current price of State Street SPDR S&P Pharmaceuticals ETF?

The current price of State Street SPDR S&P Pharmaceuticals ETF is 57.93

When was State Street SPDR S&P Pharmaceuticals ETF last traded?

The last trade of State Street SPDR S&P Pharmaceuticals ETF was at 06/05/26 10:28 AM ET

What is the market capitalization of State Street SPDR S&P Pharmaceuticals ETF?

The market capitalization of State Street SPDR S&P Pharmaceuticals ETF is 2.09M

How many shares of State Street SPDR S&P Pharmaceuticals ETF are outstanding?

State Street SPDR S&P Pharmaceuticals ETF has 2M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.